non-steroidal anti-inflammatory drugs for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 mild to moderate meta-analysis
Ravichandran CTRI/2021/05/033544		RCT	Indomethacin	paracetamol	COVID-19 mild to moderate	some concern	103/107	suggested	suggested 98 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
5 studies excluded by filtering options (0 RCT / 5 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 mild to moderate meta-analysis